ARTVArtiva Biotherapeutics, Inc.
Is it safe?
Caution warranted: heavy debt (CCC) and big price swings.
Insiders were net sellers (-$169K, 90 days to Oct 8, 2026), selling is often routine.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -91% · now 49% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can ARTV take a bad year?
The deepest fall in ARTV's price history on file is −91%; it is 49% below its high today.
Worst drawdown on file · −49% today
- Cash runway
- 4.5 years
Cash runway · burning $19M a quarter at the current rate
- Annualised volatility
- 155%
Annualised volatility · three times the market's own swing
Details›
- Cash and short-term investments
- $349M
- EBITDA, trailing twelve months
- −$94M
- Operating profit, trailing twelve months
- −$96M
- Annualised volatilitytwo years of daily moves
- 155%
- Worst drawdown on file
- −91%
- Below its 52-week high
- 49%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry